{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:59:20Z","timestamp":1790776760972,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104447","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:59:53Z","timestamp":1785538793000},"page":"104447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physicochemical developability insights into human Fab fragments with extended hypervariable loops"],"prefix":"10.1016","volume":"115","author":[{"given":"Marcel","family":"Passon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Mayerh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-9569","authenticated-orcid":false,"given":"Hristo L.","family":"Svilenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104447_bib0001","doi-asserted-by":"crossref","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104447_bib0002","first-page":"37","article-title":"Next generation of multispecific antibody engineering","volume":"7","author":"Keri","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.xphs.2026.104447_bib0003","doi-asserted-by":"crossref","first-page":"2185924","DOI":"10.1080\/19420862.2023.2185924","article-title":"Blueprint for antibody biologics developability","volume":"15","author":"Mieczkowski","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104447_bib0004","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/jps.24430","article-title":"Developability assessment during the selection of novel therapeutic antibodies","volume":"104","author":"Jarasch","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104447_bib0005","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2026.104447_bib0006","doi-asserted-by":"crossref","first-page":"1743053","DOI":"10.1080\/19420862.2020.1743053","article-title":"Predicting antibody developability profiles through early stage discovery screening","volume":"12","author":"Bailly","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104447_bib0007","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1073\/pnas.1810576116","article-title":"Five computational developability guidelines for therapeutic antibody profiling","volume":"116","author":"Raybould","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2026.104447_bib0008","first-page":"13","article-title":"Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics","volume":"6","author":"Zhang","year":"2023","journal-title":"Antib Ther"},{"key":"10.1016\/j.xphs.2026.104447_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2200540","article-title":"Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches","volume":"15","author":"Jain","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104447_bib0010","doi-asserted-by":"crossref","first-page":"1571371","DOI":"10.3389\/fimmu.2025.1571371","article-title":"Applying computational protein design to therapeutic antibody discovery - current state and perspectives","volume":"16","author":"Bielska","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0011","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s42003-024-06561-3","article-title":"Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability","volume":"7","author":"Bashour","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.xphs.2026.104447_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1074-7613(00)00006-6","article-title":"Diversity in the CDR3 region of VH is sufficient for most antibody specificities","volume":"13","author":"Xu","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104447_bib0013","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/intimm\/10.12.1801","article-title":"Preferred CDRH3 lengths for antibodies with defined specificities","volume":"10","author":"Johnson","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.xphs.2026.104447_bib0015","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2026.104447_bib0016","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review","volume":"223","author":"Mahomed","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.xphs.2026.104447_bib0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-025-09929-5","article-title":"Correlates of HIV-1 control after combination immunotherapy","volume":"650","author":"Peluso","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2026.104447_bib0018","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1002\/jps.22190","article-title":"Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies","volume":"99","author":"Yadav","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104447_bib0019","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.celrep.2018.04.101","article-title":"Conformational plasticity in broadly neutralizing HIV-1 antibodies triggers polyreactivity","volume":"23","author":"Prigent","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.xphs.2026.104447_bib0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/protein\/gzz002","article-title":"Net charge of antibody complementarity-determining regions is a key predictor of specificity","volume":"31","author":"Rabia","year":"2018","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.xphs.2026.104447_bib0021","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/pro.2809","article-title":"Robust and convenient analysis of protein thermal and chemical stability","volume":"24","author":"Niklasson","year":"2015","journal-title":"Protein Sci"},{"key":"10.1016\/j.xphs.2026.104447_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.xphs.2026.104447_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.xphs.2026.104447_bib0024","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accesible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.xphs.2026.104447_bib0025","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"key":"10.1016\/j.xphs.2026.104447_bib0026","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/ci300363c","article-title":"Automation of the CHARMM general force field (CGenFF) I: bond perception and atom typing","volume":"52","author":"Vanommeslaeghe","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.xphs.2026.104447_bib0027","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1021\/ci3003649","article-title":"Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges","volume":"52","author":"Vanommeslaeghe","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.xphs.2026.104447_bib0028","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1021\/acs.biochem.8b00592","article-title":"Tyrosine sulfation restricts the conformational ensemble of a flexible peptide, strengthening the binding affinity for an antibody","volume":"57","author":"Miyanabe","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.xphs.2026.104447_bib0029","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: a toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Michaud-Agrawal","year":"2011","journal-title":"J Comput Chem"},{"key":"10.1016\/j.xphs.2026.104447_bib0030","doi-asserted-by":"crossref","first-page":"D1140","DOI":"10.1093\/nar\/gkt1043","article-title":"SAbDab: the structural antibody database","volume":"42","author":"Dunbar","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xphs.2026.104447_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku1106","article-title":"PyIgClassify: a database of antibody CDR structural classifications","volume":"43","author":"Adolf-Bryfogle","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xphs.2026.104447_bib0032","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"McLellan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2026.104447_bib0033","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.immuni.2015.11.007","article-title":"Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans","volume":"43","author":"Garces","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104447_bib0034","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.immuni.2017.11.002","article-title":"HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage","volume":"47","author":"Landais","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104447_bib0035","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/s41467-024-47213-8","article-title":"Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104447_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01144-21","article-title":"A prevalent focused human antibody response to the influenza virus hemagglutinin head interface","volume":"12","author":"McCarthy","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.xphs.2026.104447_bib0037","series-title":"Therapeutic Antibodies: Methods and Protocols 115\u2013125","article-title":"The therapeutic antibody profiler (TAP) for computational developability assessment","author":"Raybould","year":"2022"},{"key":"10.1016\/j.xphs.2026.104447_bib0038","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s42004-024-01297-x","article-title":"Direct glycosylation analysis of intact monoclonal antibodies combining ESI MS of glycoforms and MALDI-in source decay MS of glycan fragments","volume":"7","author":"Senini","year":"2024","journal-title":"Commun Chem"},{"key":"10.1016\/j.xphs.2026.104447_bib0039","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41467-023-37365-4","article-title":"Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples","volume":"14","author":"Marie","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104447_bib0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41551-023-01074-6","article-title":"Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning","volume":"8","author":"Makowski","year":"2024","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.xphs.2026.104447_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708227","article-title":"To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1","volume":"12","author":"Griffith","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0042","doi-asserted-by":"crossref","first-page":"114801","DOI":"10.1016\/j.celrep.2024.114801","article-title":"Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions","volume":"43","author":"Chen","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.xphs.2026.104447_bib0043","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.1079731","article-title":"Antibody multispecificity mediated by conformational diversity","volume":"299","author":"James","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.xphs.2026.104447_bib0044","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s42256-025-01131-6","article-title":"Predicting the conformational flexibility of antibody and T cell receptor complementarity-determining regions","volume":"7","author":"Spoendlin","year":"2025","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.xphs.2026.104447_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1266668","article-title":"Polyreactivity of antibodies from different B-cell subpopulations is determined by distinct sequence patterns of variable region","volume":"14","author":"Lecerf","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0046","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JVI.03473-14","article-title":"A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene","volume":"89","author":"Pugach","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.xphs.2026.104447_bib0047","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/acs.molpharmaceut.1c00373","article-title":"Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties","volume":"19","author":"Gupta","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104447_bib0048","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0006-3495(00)76602-1","article-title":"The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein","volume":"78","author":"Vermeer","year":"2000","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2026.104447_bib0049","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3389\/fimmu.2018.03065","article-title":"Characterizing the diversity of the CDR-H3 loop conformational ensembles in relationship to antibody binding properties","volume":"9","author":"Fern\u00e1ndez-Quintero","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1072702","article-title":"A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0051","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1038\/s41467-025-63051-8","article-title":"Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women","volume":"16","author":"Mahomed","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104447_bib0052","doi-asserted-by":"crossref","first-page":"17876","DOI":"10.1038\/s41598-022-22435-2","article-title":"Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104447_bib0053","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1038\/s41598-022-12423-x","article-title":"Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency","volume":"12","author":"Cai","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104447_bib0054","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2516.2012.02881.x","article-title":"Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells","volume":"18","author":"Nielsen","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.xphs.2026.104447_bib0055","doi-asserted-by":"crossref","DOI":"10.1038\/srep45259","article-title":"Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability","volume":"7","author":"Julian","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104447_bib0056","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1021\/jp409805p","article-title":"Water dynamics in protein hydration shells: the molecular origins of the dynamical perturbation","volume":"118","author":"Fogarty","year":"2014","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.xphs.2026.104447_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102232","article-title":"Sulfotyrosine residues: interaction specificity determinants for extracellular protein\u2013protein interactions","volume":"298","author":"Stewart","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.xphs.2026.104447_bib0058","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic \u03b2-hairpin structure","volume":"46","author":"Lee","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104447_bib0059","doi-asserted-by":"crossref","first-page":"884110","DOI":"10.3389\/fimmu.2022.884110","article-title":"Higher affinity antibodies bind with lower hydration and flexibility in large scale simulations","volume":"13","author":"Wong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104447_bib0060","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/biom15050660","article-title":"Residue-specific structural and dynamical coupling of protein and hydration water revealed by molecular dynamics simulations","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.xphs.2026.104447_bib0061","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2026.104447_bib0062","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/19420862.2016.1222342","article-title":"Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity","volume":"8","author":"Arora","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104447_bib0063","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1021\/acs.molpharmaceut.3c00023","article-title":"Subclass effects on self-association and viscosity of monoclonal antibodies at high concentrations","volume":"20","author":"Chowdhury","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104447_bib0064","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2526550123","article-title":"Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG1 antibodies","volume":"123","author":"Heisler","year":"2026","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2026.104447_bib0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306700120","article-title":"Nonspecificity fingerprints for clinical-stage antibodies in solution","volume":"120","author":"Herling","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2026.104447_bib0066","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design","volume":"43","author":"Andrabi","year":"2015","journal-title":"Immunity"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:25:57Z","timestamp":1790774757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022354926002960"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104447","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physicochemical developability insights into human Fab fragments with extended hypervariable loops","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104447"}}